These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 18461329)

  • 1. Combination chemotherapy of biweekly irinotecan (CPT-11) plus tegafur/uracil (UFT) and leucovorin (LV) for patients with metastatic colorectal cancer: phase I/II study in Japanese patients.
    Okabayashi K; Hasegawa H; Ishii Y; Endo T; Ochiai H; Kubota T; Kitagawa Y
    Cancer Chemother Pharmacol; 2009 Feb; 63(3):501-7. PubMed ID: 18461329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
    Mackay HJ; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham MA; Uzzel M; Bailey SM; Martin C; Cunningham D
    Ann Oncol; 2003 Aug; 14(8):1264-9. PubMed ID: 12881390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV.
    Shirao K; Hoff PM; Ohtsu A; Loehrer PJ; Hyodo I; Wadler S; Wadleigh RG; O'Dwyer PJ; Muro K; Yamada Y; Boku N; Nagashima F; Abbruzzese JL
    J Clin Oncol; 2004 Sep; 22(17):3466-74. PubMed ID: 15277535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weekly irinotecan plus UFT and leucovorin as first-line chemotherapy of patients with advanced colorectal cancer.
    Méndez M; Alfonso PG; Pujol E; González E; Castañon C; Cerezuela P; López-Mateos Y; Cruz JJ
    Invest New Drugs; 2005 Jun; 23(3):243-51. PubMed ID: 15868381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I and pharmacokinetic study of tegafur-uracil/leucovorin combined with 5-fluorouracil/leucovorin and irinotecan in patients with advanced colorectal cancer.
    Chayahara N; Tamura T; Yamamori M; Kadowaki Y; Okuno T; Miki I; Tsuda M; Nishisaki H; Maeda T; Inoue Y; Okumura K; Azuma T; Kasuga M; Sakaeda T; Hirai M
    Am J Clin Oncol; 2009 Feb; 32(1):56-60. PubMed ID: 19194126
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer.
    Price T; Hill M
    Oncology (Williston Park); 2000 Oct; 14(10 Suppl 9):28-31. PubMed ID: 11098487
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I/II study of twenty-four-hour infusion of irinotecan in combination with oral UFT plus leucovorin for metastatic colorectal cancer.
    Sadahiro S; Suzuki T; Maeda Y; Tanaka A; Ishikawa K; Makuuchi H; Murayama C
    Oncology; 2009; 76(5):338-41. PubMed ID: 19307740
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A feasibility study of UFT/LV and irinotecan (TEGAFIRI) in advanced or metastatic colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG) PROG 0304.
    Ishida H; Miyake Y; Fukunaga M; Watanabe Y; Kato T; Takemoto H; Furukawa H
    Jpn J Clin Oncol; 2009 Sep; 39(9):601-5. PubMed ID: 19535386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Douillard JY; Hoff PM; Skillings JR; Eisenberg P; Davidson N; Harper P; Vincent MD; Lembersky BC; Thompson S; Maniero A; Benner SE
    J Clin Oncol; 2002 Sep; 20(17):3605-16. PubMed ID: 12202661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I/II study of irinotecan, UFT and leucovorin with hepatic arterial infusion using 5-FU in colorectal cancer patients with unresectable liver metastases.
    Yamaguchi T; Matsumoto H; Yasutome M; Mori T; Takahashi K
    Cancer Chemother Pharmacol; 2011 Mar; 67(3):629-35. PubMed ID: 20495917
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
    Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
    Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II Study of Oral Tegafur/Uracil and Leucovorin plus Bevacizumab as a First-Line Therapy for Elderly Patients with Advanced or Metastatic Colorectal Cancer.
    Mizushima T; Tamagawa H; Matsuda C; Murata K; Fukunaga M; Ota H; Hasegawa J; Tsujie M; Fukuzaki T; Hata T; Takemasa I; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
    Oncology; 2015; 89(3):152-8. PubMed ID: 25967649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized comparative study of tegafur/uracil and oral leucovorin versus parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer.
    Carmichael J; Popiela T; Radstone D; Falk S; Borner M; Oza A; Skovsgaard T; Munier S; Martin C
    J Clin Oncol; 2002 Sep; 20(17):3617-27. PubMed ID: 12202662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
    Veronese ML; Stevenson JP; Sun W; Redlinger M; Algazy K; Giantonio B; Hahn S; Vaughn D; Thorn C; Whitehead AS; Haller DG; O'Dwyer PJ
    Eur J Cancer; 2004 Mar; 40(4):508-14. PubMed ID: 14962716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of CPT-11 plus UFT in patients with advanced/recurrent colorectal cancer: Osaka Gastrointestinal Cancer Chemotherapy Study Group (OGSG): Protocol 0102.
    Tomita N; Fukunaga M; Okamura S; Narahara H; Uedo N; Ishihara R; Ishida H; Furukawa H; Gotoh M; Takiuchi H
    Jpn J Clin Oncol; 2007 Jul; 37(7):521-7. PubMed ID: 17720738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of CPT-11 and bolus 5-FU/ l-leucovorin in patients with metastatic colorectal cancer.
    Fujishima H; Kikuchi I; Miyanaga O; Ueda A; Baba E; Mitsugi K; Harada M; Nakano S
    Int J Clin Oncol; 2004 Apr; 9(2):92-7. PubMed ID: 15108040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer.
    Delord JP; Bennouna J; Artru P; Perrier H; Husseini F; Desseigne F; François E; Faroux R; Smith D; Piedbois P; Naman H; Douillard JY; Bugat R
    Br J Cancer; 2007 Aug; 97(3):297-301. PubMed ID: 17637682
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Retrospectively comparative evaluation of the first- and second-line chemotherapy with campto and oxaliplatin combined with oral tegafur/uracil (UFT)/leucovorin (LV) in patients with metastatic colorectal cancer.
    Hsiao SC; Lin JF; Chuang MT; Lee YA; Wu DL
    Int Surg; 2009; 94(4):298-303. PubMed ID: 20302025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [24 hour infusion of CPT-11/oral UFT/LV].
    Iwamoto S; Yoshioka K
    Gan To Kagaku Ryoho; 2006 Jul; 33(7):901-3. PubMed ID: 16835476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of irinotecan, leucovorin, 5-fluorouracil and tegafur/uracil for metastatic colorectal cancer.
    Kono T; Ebisawa Y; Tomita I; Chisato N; Kamiya K; Asama T; Ayabe T; Ashida T; Kohgo Y; Kasai S
    J Chemother; 2005 Apr; 17(2):224-7. PubMed ID: 15920910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.